Mohamed Mourad1,2,3, Jean-Yves Mabrut1, Madiha Chellakhi4, Mickaël Lesurtel1, Célia Prevost4, Christian Ducerf1, Agnès Rode5, Philippe Merle6, Françoise Mornex4, Kayvan Mohkam1,7. 1. Department of General Surgery & Liver Transplantation, Hospices Civils de Lyon, Croix-Rousse University Hospital, Claude-Bernard Lyon 1 University, Lyon, France. 2. Ecole Doctorale Biologie Moléculaire Intégrative et Cellulaire (BMIC), Claude Bernard Lyon 1 University, Lyon, France. 3. Department of General & Digestive Surgery, Faculty of Medicine, Alexandria University, Alexandria, Egypt. 4. Department of Oncology & Radiotherapy, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France. 5. Department of Radiology, Hospices Civils de Lyon, Croix-Rousse University Hospital, Lyon, France. 6. Department of Hepatology, Hospices Civils de Lyon, Croix-Rousse University Hospital, Lyon, France. 7. Institut National de la Santé et de la Recherche Médicale (INSERM) Unit U1052, Cancer Research Center of Lyon, Lyon, France.
Abstract
Aim: To assess neoadjuvant conformal radiotherapy (CRT) before orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) not suitable for standard locoregional treatments. Methods: Patients undergoing OLT for HCC with or without prior CRT were compared using 1:3 propensity score matching. Results: After propensity score matching, 23 patients with CRT were compared with 66 control subjects. Severe morbidity rate was 34.8 versus 24.2% in the CRT and non-CRT groups (p = 0.289). Complete pathological response was observed in 47.8% of CRT-targeted nodules. The 1-/3-/5-year disease-free survivals were 77.3, 77.3 and 68.7% in the CRT group versus 85.4, 68.0 and 61.7% in the non-CRT group (p = 0.829). Conclusion: Conformal radiotherapy represents a satisfactory neoadjuvant therapy for OLT candidates not suitable for standard HCC locoregional therapies.
Aim: To assess neoadjuvant conformal radiotherapy (CRT) before orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) not suitable for standard locoregional treatments. Methods:Patients undergoing OLT for HCC with or without prior CRT were compared using 1:3 propensity score matching. Results: After propensity score matching, 23 patients with CRT were compared with 66 control subjects. Severe morbidity rate was 34.8 versus 24.2% in the CRT and non-CRT groups (p = 0.289). Complete pathological response was observed in 47.8% of CRT-targeted nodules. The 1-/3-/5-year disease-free survivals were 77.3, 77.3 and 68.7% in the CRT group versus 85.4, 68.0 and 61.7% in the non-CRT group (p = 0.829). Conclusion: Conformal radiotherapy represents a satisfactory neoadjuvant therapy for OLT candidates not suitable for standard HCC locoregional therapies.
Authors: Lei Chen; Xiaopeng Guo; Shi Chen; Yanqiao Ren; Tao Sun; Fan Yang; Chuansheng Zheng Journal: Am J Transl Res Date: 2021-01-15 Impact factor: 4.060